These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25264118)

  • 21. Treatment of stage 3 Coats' disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach.
    Cai X; Zhao P; Zhang Q; Jin H
    Graefes Arch Clin Exp Ophthalmol; 2015 Jul; 253(7):999-1004. PubMed ID: 25794987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoschisis in the setting of Coats' disease.
    Yannuzzi NA; Tzu JH; Hess DJ; Berrocal AM
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(2):172-4. PubMed ID: 24635161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idiopathic Macular Telangiectasia Type 1 with Ruptured Retinal Arterial Macroaneurysm Post Intravitreal Bevacizumab.
    Nakhwa CP; Sindal MD
    Middle East Afr J Ophthalmol; 2015; 22(3):396-8. PubMed ID: 26180485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined photodynamic therapy and intravitreal bevacizumab injection for the treatment of adult Coats' disease: a case report.
    Kim J; Park KH; Woo SJ
    Korean J Ophthalmol; 2010 Dec; 24(6):374-6. PubMed ID: 21165239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
    Wang KY; Cheng CK
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):525-30. PubMed ID: 21951171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined intravitreal bevacizumab and argon laser treatment for Coats' disease.
    Cackett P; Wong D; Cheung CM
    Acta Ophthalmol; 2010 Mar; 88(2):e48-9. PubMed ID: 19500078
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk of Tractional Retinal Detachment Following Intravitreal Bevacizumab Along with Subretinal Fluid Drainage and Cryotherapy for Stage 3B Coats' Disease.
    Bhat V; D'Souza P; Shah PK; Narendran V
    Middle East Afr J Ophthalmol; 2016; 23(2):208-11. PubMed ID: 27162454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the diagnosis and treatment of Coats' disease.
    Yang X; Wang C; Su G
    Int Ophthalmol; 2019 Apr; 39(4):957-970. PubMed ID: 30895419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab for perifoveal telangiectasia.
    Jonas JB; Libondi T; von Baltz S; Beutelspacher S
    Acta Ophthalmol; 2011 Nov; 89(7):e607-8. PubMed ID: 20946328
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease.
    Yang Q; Wei W; Shi X; Yang L
    Acta Ophthalmol; 2016 Jun; 94(4):401-6. PubMed ID: 27150442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitrectomy for full-thickness macular hole in adult-onset Coats' disease.
    Kumar V; Kumar P; Garg G; Damodaran S
    Indian J Ophthalmol; 2017 Nov; 65(11):1246-1248. PubMed ID: 29133668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.
    Zhang L; Ke Y; Wang W; Shi X; Hei K; Li X
    Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1339-1346. PubMed ID: 29549425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolution of total retinal detachment in Coats' disease with intravitreal injection of bevacizumab.
    Zhao T; Wang K; Ma Y; Jiang YR
    Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1745-6. PubMed ID: 21080196
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia.
    Veloso CE; Vianna RN; Pelayes DE; Nehemy MB
    Ophthalmic Res; 2013; 49(4):205-8. PubMed ID: 23364325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LONG-TERM OUTCOMES OF INTRAVITREAL BEVACIZUMAB THERAPY FOR SUBRETINAL NEOVASCULARIZATION SECONDARY TO IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2.
    Toygar O; Guess MG; Youssef DS; Miller DM
    Retina; 2016 Nov; 36(11):2150-2157. PubMed ID: 27258671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary Coats' response to retinal vasculitis managed with bevacizumab.
    Chaudhary P; Varshney A; Videkar C
    Indian J Ophthalmol; 2018 Sep; 66(9):1355-1357. PubMed ID: 30127171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-VEGF therapy in a silicone oil-filled myopic eye with choroidal neovascularisation.
    Chhablani J; Narayanan R
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25870215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A population-based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes.
    Mulvihill A; Morris B
    Eye (Lond); 2010 Dec; 24(12):1802-7. PubMed ID: 20865028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review.
    Slim E; Antoun J; Kourie HR; Schakkal A; Cherfan G
    Can J Ophthalmol; 2014 Oct; 49(5):450-7. PubMed ID: 25284102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.